ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Immunotherapy series | PD-L1 status: its role as a predictive biomarker and the relevance of “borderline” status"
Episode Synopsis
PD-L1 status has long been explored as a predictive biomarker for immune checkpoint inhibitors. However, the clinical evidence for its efficacy has been mixed, so how should PD-L1 status be used in clinical practice?
In the first episode in this series on immuno-oncology, Dr Vaibhav Patel from the Icahn School of Medicine at Mount Sinai, New York, answers questions about how PD-L1 status can or cannot influence treatment decisions in oncology.
References:
Kulangara K, et al. Arch Pathol Lab Med. 2019; 143(3): 330-337
Mok S, et al. Lancet. 2019; 393(10183): 1819-1830
Pacheco J. Transl Lung Cancer Res. 2019; 8(5): 723-727
Xu Y, et al. Transl Lung Cancer Res. 2019; 8(4): 413-428
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.
In the first episode in this series on immuno-oncology, Dr Vaibhav Patel from the Icahn School of Medicine at Mount Sinai, New York, answers questions about how PD-L1 status can or cannot influence treatment decisions in oncology.
References:
Kulangara K, et al. Arch Pathol Lab Med. 2019; 143(3): 330-337
Mok S, et al. Lancet. 2019; 393(10183): 1819-1830
Pacheco J. Transl Lung Cancer Res. 2019; 8(5): 723-727
Xu Y, et al. Transl Lung Cancer Res. 2019; 8(4): 413-428
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.
More episodes of the podcast Oncology Knowledge into Practice Podcast
The ESMO 2022 Clinical Practice Guidelines for use of systemic therapy in advanced thyroid care
21/03/2023
Working together in the management of thyroid cancer: An oncologist and pathologist in conversation
23/09/2022
Tissue is Never the Issue
27/06/2022
Thyroid cancer: testing for biomarkers
01/04/2022
In God we trust